Group items matching

in title, tags, annotations or url

Pandemics have far reaching consequences that range from deaths to shutting down the economy as we have witnessed during the recent COVID19 crisis. Hence there is a need to be better prepared for such pandemics. We need to solve problems ranging from predictive analytics innovative devices for saving lives to technology for devising voting machines. The social and economic impact for the above areas is huge and some of the work can be transformative and save lives. Areas of interest to us include, but are not limited to: - Mathematical models for spread and the impact of pandemics. - Scalable simulation techniques for pandemics (e.g. with multi agents). - Biomedical/Nano sensor devices for detecting symptoms and agents. - Algorithms for rapid exploration of the drug screening and discovery workflows (e.g. use reinforcement learning) - Advanced computational biology techniques for sequencing, detecting viral evolution (e.g. in COVID-19). - Algorithms and systems for contact tracing (with privacy preserving). - Algorithms and recommendation systems for curating media and news. - Collaboration techniques for more effective health, and efficiency during pandemics. Improved identity and security techniques. - Distributed Ledgers, their applications and their governance for and during pandemics. - Pandemic data science - understanding the patterns and the impact of a pandemic like COVID-10. Creation of curated data sets. We are interested in both the science and technology aspects of these problem sets, and, particularly, in the intersections between them.

The Division of Mathematical Sciences (DMS)in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF)and the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH)plan to support fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. Both agencies recognize the need to promote research at the interface between mathematical and life sciences. This program is designed to encourage new collaborations, as well as to support innovative activities by existing teams.

The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.

The Searle Scholars Program makes grants to selected universities and research centers to support the independent research of exceptional young faculty in the biomedical sciences and chemistry who have recently been appointed as assistant professors on a tenure-track appointment. The Program's Scientific Director appoints an Advisory Board of eminent scientists who choose the Scholars based on rigorous standards aimed at finding the most creative talent interested in pursuing an academic research career.

The Rita Allen Foundation Scholars program funds basic biomedical research in the fields of cancer, immunology, and neuroscience, as well as pain through the Rita Allen Foundation Award in Pain. Rita Allen Foundation Scholars are distinguished by their bold approaches to basic scientific questions that address problems of global concern, as well as their potential for learning, leadership and collaboration.

The Amyloidosis Foundation grant program supports basic biomedical and clinical research on systemic amyloidosis. Applicants who are within 10 years of completion of post-doctoral studies or clinical fellowship are eligible to apply for funding. Applicants must have a mentor, who guarantees an environment taht will support the research project of the applicant.

The Greenwall Faculty Scholars Program in Bioethics is a career development award to enable junior faculty members to carry out innovative bioethics research. It supports research that goes beyond current work in bioethics to help resolve pressing ethical issues in clinical, biomedical, and public health decision-making, policy, and practice, and creates a community that enhances future bioethics research by Scholars and Alumni/ae. Each year, the Foundation selects approximately three Greenwall Faculty Scholars to receive 50 percent salary support for three years to enable them to carry out a specific research proposal and develop their research program. Scholars and Alumni/ae attend twice-yearly meetings, where they present their works in progress, receive feedback and mentoring from the Faculty Scholars Program Committee and other Scholars and Alumni/ae, and have the opportunity to develop collaborations with other researchers. The ongoing involvement of Alumni/ae with the Program provides them ongoing opportunities for professional development and feedback and engages them in mentoring of younger Scholars.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), the Division of Epidemiology, Statistics, and Prevention Research intends to solicit proposals to award an Indefinite Delivery Indefinite Quantity (IDIQ) contract to an organization to conduct various studies focusing on a spectrum of health effects in men, women, and children that rely on quantification of analytes in biological specimens such as blood, urine, adipose tissue, follicular fluids, and seminal fluids.  The Division needs a variety of banked specimens analyzed for concentrations of various hormone levels, dietary biomarkers, and indicators of metabolic function among other analytes.

The Collaborative Research Travel Grant (CRTG) program provides up to $15,000 in support for researchers from degree-granting institutions to travel either domestically or internationally to a laboratory to acquire a new research technique or to facilitate a collaboration. To capitalize on what appears to be an opportunity to provide relatively unrestricted travel funds to academic scientists and trainees and to provide a stimulus for those working or contemplating working at the interface of science, this program provides travel grants that can be used both internationally and domestically to acquire new research techniques, and to promote collaborations. 

The University of South Alabama offers an interdisciplinary undergraduate research program sponsored by the National Science Foundation to work for 10 weeks over the summer semester in the area of "Structure and Function of Proteins".  Students accepted to the program must have a strong interest in basic research, and are expected to work full time in their projects under the direction of faculty advisors. Important Information Applicants must be US citizens or Permanent Residents (Green Card). Students must have completed one of the following courses or course sequences before the summer: Organic Chemistry sequence, Biochemistry sequence, Thermodynamics or Statics. All participants receive a stipend, free housing, food allowance and travel expenses. Minimum GPA of 3.0 or higher. Neither the University of South Alabama nor the National Science Foundation can provide health insurance to participants in the program. All participants are fully responsible for their own health insurance coverage. Accepted students are required to adhere to all policies of the University of South Alabama Student Handbook (The Lowdown) and Residence Life Handbook

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers.  The purpose of this FOA is to develop Immuno-engineering to Improve Immunotherapy (i3) Centers, as new components of the Immuno-Oncology Translation Network (IOTN). The i3 Centers will be comprised of multi-disciplinary teams focused on developing and employing engineered immunotherapy approaches to design more durable, widely accessible, and less toxic immunoprevention and immunotherapy strategies. The overarching goals of the IOTN are to accelerate translational research of innate and adaptive immune mechanisms that contribute to tumor progression, and evaluate new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints. 

This funding opportunity announcement (FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for development of new compounds and improvement of existing ligand specificity and selectivity, initial screening of ligands in appropriate animal models, and radioligand formulation and first-in-human testing. The Center without Walls should encompass research that will move promising ligands through in vitro and in vivo optimization to first-in-human studies. Applications must include an administrative core, a medicinal chemistry core, a clinical core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.

The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations to develop and implement the use of 3D biofabricated tissue models as novel drug screening platforms and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder (OUD) and/or overdose. In particular, support during the UH2 phase is for the application of 3D biofabrication technologies to develop novel multicellular tissue constructs for drug screening by using human iPSC-derived cells representing sensory/pain neurons, brain regions, and other tissues involved in nociception, addiction and/or overdose, including tissue models of the blood-brain barrier (BBB). Support during the UH3 is for implementation of drug screens using the 3D tissue models developed during the UH2 phase. Please limit this field to a brief description of to page in length. Brevity is appreciated. This FOA is part of the of the NIHs Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative

The primary purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success, and also behavioral and social science research projects to study contraceptive use and non-use of marketed products or products in clinical development. The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

The National Institute on Aging invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.

The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Half of all Crohn's disease patients will develop disease complications, one of which is development of fibrotic strictures (fibrostenosis) leading to GI tract obstruction and severe clinical consequences. Fibrostenosis is also a serious problem for ulcerative colitis, with approximately 8 percent incidence over a lifetime. Currently there is no clinical solution for preventing or treating fibrostenosis in patients with inflammatory bowel disease (IBD) except for surgical intervention. Therefore, there is a great unmet need to understand fibrotic complications in IBD and how to prevent and treat them.

This notice of funding opportunity (NOFO) supports the acceleration of a comprehensive HIV prevention, care, and treatment program to achieve HIV epidemic control in selected Health Zones (HZs) in Kinshasa province. This aims to provide evidence-based interventions, including targeted HIV testing, to find more people living with HIV (PLHIV), especially among eligible contacts of HIV positive index cases, as well as community outreach through Orphan and Vulnerable Children (OVC) services; HIV prevention services; TB/HIV prevention, diagnosis, and treatment services; Prevention of Mother-to-Child Transmission (PMTCT) for general population and key population (KP); and associated laboratory and strategic information (SI) services. Through a stigma-free approach, the recipient will provide direct support and technical assistance to accelerate the HIV service delivery cascade and improve data quality and utilization for decision-making. The recipient will also work closely with the Ministry of Health (MOH) to strengthen the technical capacity of provincial and HZ Teams. Capable community organizations are expected to contribute by improving uptake of HIV services, linkage, and retention. The ultimate goal is the elimination of HIV by 2030.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

The purpose of this Funding Opportunity Announcement (FOA) is to incentivize collaborative, multidisciplinary research across a broad area of challenging topics in basic cancer biology. These supplement applications must propose a collaboration between at least two researchers, one being the PI of the parent NCI grant. Awarded supplements will leverage and extend currently funded cancer research in the parent grant.